<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2108">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133713</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000091</org_study_id>
    <nct_id>NCT05133713</nct_id>
  </id_info>
  <brief_title>Ventilation and Perfusion Scan in Pulmonary Embolism Following Catheter Directed Thrombectomy Versus Anticoagulation Alone</brief_title>
  <acronym>VQPE</acronym>
  <official_title>Ventilation and Perfusion Imaging in Acute Pulmonary Embolism Following Catheter Directed Aspiration Thrombectomy Versus Conservative Therapy Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inari Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical presentation of acute pulmonary embolism (PE) is complex and varied and not&#xD;
      uncommonly involves respiratory failure with dyspnea or hypoxia. Patients with persisting&#xD;
      signs of respiratory failure despite anticoagulation, may benefit from catheter directed&#xD;
      thrombectomy. Additionally, patient who receive thrombectomy are likely to have a lower&#xD;
      residual thrombus burden measurable by ventilation-perfusion (V/Q) scan, and thereby less&#xD;
      likely to develop chronic sequela, including chronic thromboembolic pulmonary hypertension&#xD;
      (CTEPH) and post PE syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute pulmonary embolism (PE) is a common disease with variable presentation and clinical&#xD;
      outcomes. Chronic sequelae including chronic thromboembolic pulmonary hypertension (CTEPH)&#xD;
      and post-PE syndrome are common pathologies for patient who survive the already significant&#xD;
      inpatient mortality, and have a significant impact on both quality of life and life&#xD;
      expectancy. To date, the ELOPE trial is the only study to prospectively compare quality of&#xD;
      life (QoL) and dyspnea measures and six-minute walk distance (6MWD) to cardiopulmonary&#xD;
      exercise test, revealing worse post-PE syndrome in select populations, however this study is&#xD;
      limited to a single arm that received anticoagulation alone. New catheter directed therapies,&#xD;
      developed in response to such poor outcomes, provide treatment options for acute PE patients&#xD;
      when first line therapies including anticoagulation are contraindicated or have failed.&#xD;
&#xD;
      Long term studies utilizing imaging have shown a majority of patients diagnosed with PE have&#xD;
      residual pulmonary thrombi after 6 months, which is likely to be a large contributor to the&#xD;
      development of CTEPH. Ventilation-perfusion (V/Q) scans remain the gold standard for&#xD;
      detection of both acute and chronic pulmonary embolism and will serve as a primary outcome&#xD;
      measure at 6 months post initial treatment. Clinical measures including 6MWD, QoL and dyspnea&#xD;
      questionaries will be assessed prior to discharge, and at 3 and 6 months, in order to&#xD;
      characterize the development of chronic symptomatology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Ventilation-perfusion mismatch</measure>
    <time_frame>6 months</time_frame>
    <description>Mismatch on ventilation-perfusion scintigraphy per Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-minute walk distance</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk distance</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk distance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea questionnaire</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Chronic Thromboembolic Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Catheter directed thrombectomy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic anticoagulation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Catheter directed therapy</intervention_name>
    <description>Thrombectomy</description>
    <arm_group_label>Catheter directed thrombectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systemic anticoagulation</intervention_name>
    <description>Conservative therapy</description>
    <arm_group_label>Catheter directed thrombectomy</arm_group_label>
    <arm_group_label>Systemic anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients requiring treatment for acute pulmonary embolism.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18 years&#xD;
&#xD;
          2. Clinical signs and symptoms consistent with acute PE&#xD;
&#xD;
          3. Echocardiogram, CT pulmonary angiogram (CTPA) or pulmonary angiographic evidence of&#xD;
             proximal filling defect in at least one main or lobar pulmonary artery&#xD;
&#xD;
          4. Scheduled for PE treatment with catheter directed therapy and systemic anticoagulation&#xD;
             or anticoagulation alone per the investigator's discretion&#xD;
&#xD;
          5. Signs of respiratory failure including a. arterial blood saturation &lt;90%, or b.&#xD;
             partial arterial oxygen pressure &lt;60 mmHg, or c. persistent tachypnea with respiratory&#xD;
             rates &gt; 20/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to be anticoagulated with heparin or alternative therapy&#xD;
&#xD;
          2. Diagnosis with a minor PE without signs of right ventricular (RV) dysfunction&#xD;
&#xD;
          3. Known sensitivity to radiographic contrast agents that, in the Investigator's opinion,&#xD;
             cannot be adequately pre-treated&#xD;
&#xD;
          4. Imaging evidence or other evidence that suggests, in opinion of the Investigator, the&#xD;
             patient is not appropriate for mechanical thrombectomy intervention (e.g., inability&#xD;
             to navigate to target location or predominately chronic clot)&#xD;
&#xD;
          5. Life expectancy &lt;6 months, as determined by the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Carol Stuehm</last_name>
    <phone>520-626-8318</phone>
    <email>carols@email.arizona.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner University Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Michael Kendall, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdul Khan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tammer El-Aini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Insel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999 Apr 24;353(9162):1386-9.</citation>
    <PMID>10227218</PMID>
  </reference>
  <reference>
    <citation>Casazza F, Becattini C, Bongarzoni A, Cuccia C, Roncon L, Favretto G, Zonzin P, Pignataro L, Agnelli G. Clinical features and short term outcomes of patients with acute pulmonary embolism. The Italian Pulmonary Embolism Registry (IPER). Thromb Res. 2012 Dec;130(6):847-52. doi: 10.1016/j.thromres.2012.08.292. Epub 2012 Aug 24.</citation>
    <PMID>22921592</PMID>
  </reference>
  <reference>
    <citation>Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011 Jan 27;364(4):351-60. doi: 10.1056/NEJMra0910203. Review.</citation>
    <PMID>21268727</PMID>
  </reference>
  <reference>
    <citation>Kahn SR, Akaberi A, Granton JT, Anderson DR, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Hernandez P, Aaron SD, Hirsch AM. Quality of Life, Dyspnea, and Functional Exercise Capacity Following a First Episode of Pulmonary Embolism: Results of the ELOPE Cohort Study. Am J Med. 2017 Aug;130(8):990.e9-990.e21. doi: 10.1016/j.amjmed.2017.03.033. Epub 2017 Apr 8.</citation>
    <PMID>28400247</PMID>
  </reference>
  <reference>
    <citation>Nijkeuter M, Hovens MM, Davidson BL, Huisman MV. Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review. Chest. 2006 Jan;129(1):192-7. Review.</citation>
    <PMID>16424432</PMID>
  </reference>
  <reference>
    <citation>Kahn SR, Hirsch AM, Akaberi A, Hernandez P, Anderson DR, Wells PS, Rodger MA, Solymoss S, Kovacs MJ, Rudski L, Shimony A, Dennie C, Rush C, Geerts WH, Aaron SD, Granton JT. Functional and Exercise Limitations After a First Episode of Pulmonary Embolism: Results of the ELOPE Prospective Cohort Study. Chest. 2017 May;151(5):1058-1068. doi: 10.1016/j.chest.2016.11.030. Epub 2016 Dec 6.</citation>
    <PMID>27932051</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Gregory Woodhead</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

